ClinicalTrials.gg

Program

omaveloxolone

Also written as “Omaveloxolone”, “Omaveloxolone Capsules, 2.5 mg” and “Omaveloxolone Capsules, 5 mg”.

Its studies are mostly in Friedreich Ataxia · Inflammation · Mitochondrial Myopathies · Melanoma · Breast Neoplasms, led by Biogen.

Furthest: phase 3, since Apr 11, 202519 company-led studies, 2 open or runningNext primary completion: Nov 16, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogen192 open or runningphase 3since Apr 11, 2025Dec 30, 2013Nov 16, 2027phase 3 · NCT06953583

Also a collaborator on its studies: AbbVie, celerion, q2-solutions, altasciences-company-inc and covance.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Dec 30, 2013.

  1. May 16, 2014Phase 2 study in Breast NeoplasmsNCT02142959 · 187 enrolled · United States
  2. Sep 30, 20142 phase 2 studiesNCT02255435, NCT02255422
  3. Oct 3, 2014Phase 2 study in MelanomaNCT02259231 · 41 enrolled · United States
  4. Sep 6, 2018Phase 1 study in HealthyNCT03664453 · 32 enrolled · United States
  5. Mar 26, 2019Phase 1 study in Hepatic ImpairmentNCT03902002 · 48 enrolled · United States
  6. Apr 25, 2019Phase 1 study in Healthy Male SubjectsNCT03931590 · 8 enrolled · United States
  7. Jul 2, 2019Phase 1 study in Healthy Adult SubjectsNCT04008186 · 61 enrolled · United States
  8. Jun 8, 20232 phase 1 studiesNCT05909644, NCT05927649
  9. Sep 13, 2023Phase 1 study in Friedreich AtaxiaNCT06054893 · 33 enrolled · United States
  10. Sep 23, 2024Phase 1 study in Healthy VolunteerNCT06612879 · 12 enrolled · United States
  11. Apr 11, 2025Phase 3 study in Friedreich AtaxiaNCT06953583 · 255 enrolled · United States, Australia, Austria and more
  12. Jun 5, 2025Phase 1 study in Healthy VolunteerNCT07019064 · 52 enrolled · United States
  13. Aug 28, 2025Phase 1 study in Healthy VolunteerNCT07149415 · 22 enrolled · United States
  14. Dec 9, 2025Phase 1 study in Healthy VolunteerNCT07297199 · 70 enrolled · United States

Ahead

  1. Nov 16, 2027Primary completion: phase 3 study in Friedreich AtaxiaNCT06953583
  2. Jun 4, 2030Primary completion: phase 1 study in Friedreich AtaxiaNCT06054893

TargetBeta

NFE2L2 →read by rule
“Nuclear factor erythroid 2-related factor 2 activator”ChEMBL 37, by rule

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07297199Healthy Volunteer · United States1CompletedMay 1, 202670
NCT07149415Healthy Volunteer · United States1CompletedOct 16, 202522
NCT07019064Healthy Volunteer · United States1CompletedAug 19, 202552
NCT06953583Friedreich Ataxia · United States, Australia, Austria and more3Active, not recruitingNov 16, 2027255
NCT06612879Healthy Volunteer · United States1CompletedMar 11, 202512
NCT06054893Friedreich Ataxia · United States1Active, not recruitingJun 4, 203033
NCT05927649Health Adult Subjects · United States1CompletedSep 1, 202330
NCT05909644Healthy Adult Subjects · United States1CompletedAug 30, 202320
NCT04008186Healthy Adult Subjects · United States1CompletedAug 18, 201961
NCT03931590Healthy Male Subjects · United States1CompletedMay 31, 20198
NCT03902002Hepatic Impairment · United States1CompletedJan 27, 202048
NCT03664453Healthy · United States1CompletedNov 20, 201832
NCT02259231Melanoma · United States2CompletedMay 9, 201841
NCT02255435Friedreich Ataxia · United States, Australia, Austria and more2CompletedOct 31, 2019172
NCT02255422Mitochondrial Myopathies · United States, Denmark2CompletedNov 2, 201753
NCT02142959Breast Neoplasms · United States2CompletedApr 30, 2015187
NCT02065375Inflammation · United States2CompletedSep 30, 2014109
NCT02029729Neoplasm Metastasis · United States1CompletedOct 1, 201511
NCT02029716Inflammation · United States1CompletedApr 1, 2014109

How it is read

Names in the registry

  • “Omaveloxolone”, 9 entries
  • “omaveloxolone”, 2 entries
  • “Omaveloxolone Capsules, 2.5 mg”, 1 entry
  • “Omaveloxolone Capsules, 5 mg”, 1 entry
  • “Omaveloxolone Capsules, 10 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.